280 related articles for article (PubMed ID: 28588015)
1. Intravesical BCG Induces CD4
Kates M; Nirschl T; Sopko NA; Matsui H; Kochel CM; Reis LO; Netto GJ; Hoque MO; Hahn NM; McConkey DJ; Baras AS; Drake CG; Bivalacqua TJ
Cancer Immunol Res; 2017 Jul; 5(7):594-603. PubMed ID: 28588015
[TBL] [Abstract][Full Text] [Related]
2. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
3. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
4. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
Kates M; Matoso A; Choi W; Baras AS; Daniels MJ; Lombardo K; Brant A; Mikkilineni N; McConkey DJ; Kamat AM; Svatek RS; Porten SP; Meeks JJ; Lerner SP; Dinney CP; Black PC; McKiernan JM; Anderson C; Drake CG; Bivalacqua TJ
Clin Cancer Res; 2020 Feb; 26(4):882-891. PubMed ID: 31712383
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
[TBL] [Abstract][Full Text] [Related]
7. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
8. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
9. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
10. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer.
Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K
Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835
[TBL] [Abstract][Full Text] [Related]
12. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.
Ratliff TL; Ritchey JK; Yuan JJ; Andriole GL; Catalona WJ
J Urol; 1993 Sep; 150(3):1018-23. PubMed ID: 8102183
[TBL] [Abstract][Full Text] [Related]
13. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
[TBL] [Abstract][Full Text] [Related]
14. Baseline Cytokine Profiles of Tuberculin-Specific CD4
Jallad S; Thomas P; Newport MJ; Kern F
Cancer Immunol Res; 2018 Oct; 6(10):1212-1219. PubMed ID: 30120103
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
[TBL] [Abstract][Full Text] [Related]
19. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.
Bunimovich-Mendrazitsky S; Claude Gluckman J; Chaskalovic J
J Theor Biol; 2011 May; 277(1):27-40. PubMed ID: 21334346
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis.
Elsäßer J; Janssen MW; Becker F; Suttmann H; Schmitt K; Sester U; Stöckle M; Sester M
PLoS One; 2013; 8(9):e69892. PubMed ID: 24039703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
